search
Back to results

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Primary Purpose

Lymphoma

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Sponsored by
Ruijin Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histological detection confirmed CD19/CD22 postive lymphoma;
  • Recieved more than 2 lines of chemotherapy;
  • Not eligible for hematopoietic stem cell transplantation or relapsed after hematopoietic stem cell transplantation;
  • Life expectation for more than 3 months;
  • ECOG ≥ 2;
  • Adequate organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT < 2 × upper limitation of normal; SpO2 > 92%;
  • CBC results: Hb ≥ 80g/L, ANC > 1 × 10E9/L, Plt ≥ 50 × 10E9/L;
  • Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion;
  • With measurable disease;
  • Written informed consent could be acquired;

Exclusion Criteria:

  • Immunosuppressive agents or steroids in recent 1 week before recruitment;
  • Uncontrolled infection;
  • HIV positive ;
  • Active HBV or HCV infection;
  • Women in pregnancy and lactation;
  • Refuse to conception control during treatment and 1 year after CAR-T infusion;
  • Uncured malignancies other than non-Hodgkin lymphoma;
  • Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma;
  • Inheritated immune deficiancy;
  • Severe heart disease.

Sites / Locations

  • Shanghai Ruijin HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CAR-T cell therapy

Arm Description

Patient-derived dual specificity CD19 and CD22 CAR-T

Outcomes

Primary Outcome Measures

Overall remission rate
Rate of complete remission and patial remission

Secondary Outcome Measures

Adverse toxicity
According to CTCAE 4.0 criteria

Full Information

First Posted
March 11, 2018
Last Updated
March 16, 2018
Sponsor
Ruijin Hospital
Collaborators
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03468153
Brief Title
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Official Title
The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
January 1, 2019 (Anticipated)
Study Completion Date
January 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ruijin Hospital
Collaborators
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Patients with relapsed or refractory lymphoma often develop resistance to chemotherapy. Chimeric antigen receptor-modified T cell (CART) therapy showed promising effect in B-cell malignancies these years. CD19 and CD22 are proteins expressed on the surface of the lymphoma cells in patients with CD19+CD22+ lymphoma. The CAR enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22. This is a phase 2 trial to study the safety and efficacy of dual specificity CD19 and CD22 CAR-T cell immunotherapy for CD19+CD22+ relapsed and refractory lymphoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CAR-T cell therapy
Arm Type
Experimental
Arm Description
Patient-derived dual specificity CD19 and CD22 CAR-T
Intervention Type
Biological
Intervention Name(s)
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Intervention Description
Patient-derived dual specificity CD19 and CD22 CAR-T Cells
Primary Outcome Measure Information:
Title
Overall remission rate
Description
Rate of complete remission and patial remission
Time Frame
4 weeks after infusion
Secondary Outcome Measure Information:
Title
Adverse toxicity
Description
According to CTCAE 4.0 criteria
Time Frame
Day 0, day 4, week 1, week 3, week 4, month 2, month 12 after CAR-T cells were infused

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histological detection confirmed CD19/CD22 postive lymphoma; Recieved more than 2 lines of chemotherapy; Not eligible for hematopoietic stem cell transplantation or relapsed after hematopoietic stem cell transplantation; Life expectation for more than 3 months; ECOG ≥ 2; Adequate organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT < 2 × upper limitation of normal; SpO2 > 92%; CBC results: Hb ≥ 80g/L, ANC > 1 × 10E9/L, Plt ≥ 50 × 10E9/L; Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion; With measurable disease; Written informed consent could be acquired; Exclusion Criteria: Immunosuppressive agents or steroids in recent 1 week before recruitment; Uncontrolled infection; HIV positive ; Active HBV or HCV infection; Women in pregnancy and lactation; Refuse to conception control during treatment and 1 year after CAR-T infusion; Uncured malignancies other than non-Hodgkin lymphoma; Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma; Inheritated immune deficiancy; Severe heart disease.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Weili Zhao, MD
Phone
64370045
Ext
610707
Email
zhao.weili@yahoo.com
Facility Information:
Facility Name
Shanghai Ruijin Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weili Zhao, MD
Phone
64370045
Ext
610707
Email
zhao.weili@yahoo.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

We'll reach out to this number within 24 hrs